Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine and Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Pleasanton, CA and Tokyo, Japan, June 6th, 2019. Astex Pharmaceuticals, Inc. a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials